CHF6001 I: A novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 3, 2015, Pages 559-567

  Moretto, Nadia ^a   Caruso, Paola ^a   Bosco, Raffaella ^a   Marchini, Gessica ^a   Pastore, Fiorella ^a   Armani, Elisabetta ^a   Amari, Gabriele ^a   Rizzi, Andrea ^a   Ghidini, Eleonora ^a   De Fanti, Renato ^a   Capaldi, Carmelida ^a   Carzaniga, Laura ^a   Hirsch, Emilio ^b   Buccellati, Carola ^c   Sala, Angelo ^c   Carnini, Chiara ^a   Patacchini, Riccardo ^a   Delcanale, Maurizio ^a   Civelli, Maurizio ^a   Villetti, Gino ^a   Facchinetti, Fabrizio ^a   more..

^a CHIESI FARMACEUTICI S P A   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Dipartimento di Scienze Farmacologiche e Biomolecolari   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,5 DICHLORO 4 [2 [3 (CYCLOPROPYLMETHOXY) 4 (DIFLUOROMETHOXY)PHENYL] 2 [3 (CYCLOPROPYLMETHOXY) 4 (METHYLSULFONAMIDO)BENZOYLOXY]ETHYL]PYRIDINE 1 OXIDE; BACTERIUM LIPOPOLYSACCHARIDE; BUDESONIDE; CILOMILAST; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; GSK 256066; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; [2 (3,4 DIFLUOROPHENOXY) 5 FLUORO N 4 (2 HYDROXY 5 METHYLBENZAMIDO)CYCLOHEXYL]NICOTINAMIDE; ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BINDING SITE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SELECTIVITY; DRY POWDER; ENZYME INHIBITION; EOSINOPHIL; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NEUTROPHILIA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RAT; RESPIRATORY BURST; SALMONELLA ENTERICA; ANIMAL; BROWN NORWAY RAT; C57BL MOUSE; FERRET; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; FERRETS; MALE; MICE, INBRED C57BL; PHOSPHODIESTERASE 4 INHIBITORS; RATS; RATS, INBRED BN; RATS, SPRAGUE-DAWLEY;

EID: 84922031641     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.220541     Document Type: Article

References (39)

1. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay M, and Taskén K (2004) TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol 173:4847-4858.
2. Ariga M, Neitzert B, Nakae S, Mottin G, Bertrand C, Pruniaux MP, Jin SL, and Conti M (2004) Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation. J Immunol 173:7531-7538.
3. Armani E, Amari G, Rizzi A, De Fanti R, Ghidini E, Capaldi C, Carzaniga L, Caruso P, Guala M, Peretto I, et al. (2014) Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem 57:793-816.
4. Baehr W, Devlin MJ, and Applebury ML (1979) Isolation and characterization of cGMP phosphodiesterase from bovine rod outer segments. J Biol Chem 254:11669-11677.
5. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, and Torphy TJ (1996) Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem Pharmacol 51: 949-956.
6. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, and Torphy TJ (1998) SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 284:420-426.
7. Bender AT and Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488-520.
8. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, and Martinez FJ; M2-124 and M2-125 Study Groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694.
9. Daigneault M, Preston JA, Marriott HM, Whyte MK, and Dockrell DH (2010) The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 5:e8668.
10. Esposito O, Mariotti F, Acerbi D, Compagnoni A, and Nandeuil MA (2013) Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers. Eu Respir J 42 (Suppl 57):736.
11. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Arcidiacono D, and Leon A (2004) Dopamine inhibits responses of astroglia-enriched cultures to lipopolysaccharide via a beta-adrenoreceptor-mediated mechanism. J Neuroimmunol 150:29-36.
12. Fan Chung K (2006) Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533:110-117.
13. Gantner F, Kupferschmidt R, Schudt C, Wendel A, and Hatzelmann A (1997) In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 121:221-231.
14. Giembycz MA and Field SK (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4 :147-158.
15. Gietzen K, Sadorf I, and Bader H (1982) A model for the regulation of the calmodulin-dependent enzymes erythrocyte Ca2+-transport ATPase and brain phosphodiesterase by activators and inhibitors. Biochem J 207:541-548.
16. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, and Tenor H (2010) The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235-256.
17. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
18. Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, and Shimizu Y (2012) Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor. Int Immunopharmacol 12:59-63.
19. Kumar RK, Webb DC, Herbert C, and Foster PS (2006) Interferon-gamma as a possible target in chronic asthma. Inflamm Allergy Drug Targets 5:253-256.
20. MacKenzie SJ, Hastings SF, and Well C (2010) Cyclic nucleotide phosphodiesterase assay technology. Curr Prot Pharmacol 49(Suppl):12.1-26.
21. Martorana PA, Beume R, Lucattelli M, Wollin L, and Lungarella G (2005) Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172:848-853.
22. Moretto N, Caruso P, Bosco R, Marchini G, Pastore F, Armani E, Amari G, Rizzi A, Ghidin E, De Fanti R, et al. (2014) CHF6001 is a novel highly potent and selective phosphodiesterase 4 (pde4) inhibitor with a robust in vitro anti-inflammatory profile. Am J Respir Crit Care Med 189:A6725.
23. Nials AT, Tralau-Stewart CJ, Gascoigne MH, Ball DI, Ranshaw LE, and Knowles RG (2011) In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 337:137-144.
24. Page CP and Spina D (2011) Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handbook Exp Pharmacol 204:391-414.
25. Pagès L, Gavaldà A, and Lehner MD (2009) PDE4 inhibitors: a review of current developments (2005 - 2009). Expert Opin Ther Pat 19:1501-1519.
26. Press NJ and Banner KH (2009) PDE4 inhibitors - a review of the current field. Prog Med Chem 47:37-74.
27. Quint JK and Wedzicha JA (2007) The neutrophil in chronic obstructive pulmonary disease. J Allergy Clin Immunol 119:1065-1071.
28. Rocque WJ, Tian G, Wiseman JS, Holmes WD, Zajac-Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC, Kadwell SH, et al. (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry 36:14250-14261.
29. Schudt C, Winder S, Forderkunz S, Hatzelmann A, and Ullrich V (1991) Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol 344:682-690.
30. Singh D, Petavy F, Macdonald AJ, Lazaar AL, and O'Connor BJ (2010) The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res 11:11-26.
31. Souness JE and Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236.
32. Spina D (2003) Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 63:2575-2594.
33. Srivani P, Usharani D, Jemmis ED, and Sastry GN (2008) Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. Curr Pharm Des 14:3854-3872.
34. Thompson WJ and Appleman MM (1971) Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10:311-316.
35. Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ, Angell AD, Solanke YE, Lucas FS, Wiseman J, et al. (2011) GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther 337:145-154.
36. Vestbo J, Tan L, Atkinson G, and Ward J; UK-500,001 Global Study Team (2009) A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 33:1039-1044.
37. Villetti G, Carnini C, Battipaglia L, Preynat L, Bolzoni PT, Bassani F, Caruso P, Bergamaschi M, Pisano AR, Puviani V, et al. (2015) CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration - in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window. J Pharmacol Exp Ther 352:568-578.
38. Watt AP, Schock BC, and Ennis M (2005) Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr Drug Targets Inflamm Allergy 4:415-423.
39. Watz H, Mistry SJ, and Lazaar AL; IPC101939 investigators (2013) Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther 26:588-595.